Precigen (PGEN) Common Equity (2011 - 2026)

Precigen (PGEN) has 16 years of Common Equity data on file, last reported at $20.2 million in Q1 2026.

• Common Equity for Q1 2026 came in at $20.2 million, up 243.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.2 million (up 243.92% YoY), and the FY2025 annual result was $20.9 million, down 45.7% from the prior year.
• Common Equity declined to $20.2 million in Q1 2026 per PGEN's latest filing, from $20.9 million in the prior quarter.
• Over five years, Common Equity peaked at $184.1 million in Q1 2023 and troughed at -$36.8 million in Q2 2025.
• A 5-year average of $75.4 million and a median of $55.7 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity plunged 185.2% in 2025, then soared 243.92% in 2026.
• A 5-year view of Common Equity shows it stood at $126.3 million in 2022, then dropped by 6.15% to $118.5 million in 2023, then tumbled by 67.5% to $38.5 million in 2024, then slumped by 45.7% to $20.9 million in 2025, then declined by 3.23% to $20.2 million in 2026.
• Business Quant data shows PGEN's Common Equity at $20.2 million in Q1 2026, $20.9 million in Q4 2025, and $41.9 million in Q3 2025.